English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Approximately 15% of newly diagnosed patients present with T-lineage acute lymphoblastic leukemia (T-ALL).1 When matched for National Cancer Institute (NCI) risk criteria, patients with T-ALL are at greater risk of relapse than those with B-cell precursor ALL (BCP-ALL), warranting specialized therapies. Unlike BCP-ALL, where molecular abnormalities are commonly utilized for risk-adapted treatment,2 the recurring molecular lesions found in T-ALL are not.

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children’s Oncology Group Study